Alec Stranahan
Stock Analyst at B of A Securities
(0.71)
# 4,094
Out of 5,140 analysts
32
Total ratings
40%
Success rate
-40.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $182 → $255 | $290.81 | -12.31% | 5 | Oct 17, 2025 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $6.50 | +7.69% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $13.40 | -10.45% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $10.42 | -90.40% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $9.65 | -27.46% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $34.78 | +20.76% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $12.70 | +96.85% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.63 | +574.85% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.71 | +121.40% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.35 | +538.30% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $119.68 | -54.04% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $31.37 | -80.87% | 2 | Dec 29, 2022 |
Krystal Biotech
Oct 17, 2025
Maintains: Buy
Price Target: $182 → $255
Current: $290.81
Upside: -12.31%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $6.50
Upside: +7.69%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $13.40
Upside: -10.45%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $10.42
Upside: -90.40%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $9.65
Upside: -27.46%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $34.78
Upside: +20.76%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $12.70
Upside: +96.85%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.63
Upside: +574.85%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.71
Upside: +121.40%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.35
Upside: +538.30%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $119.68
Upside: -54.04%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $31.37
Upside: -80.87%